TABLE 4.
Phase II IgM: statistical analysis of four commercial ELISA kits compared to IFATa
| ELISA test phase II IgM | Total no. of tests | No. of IFAT-positive results | % (95% CI) |
P (χ2 test) | |
|---|---|---|---|---|---|
| Sensitivity | Specificity | ||||
| Virion/Serion | 43 | 29 | 93.1 (77.23–99.15) | 50.00 (23.04–76.96) | 1.13E−03 |
| Biomed | 43 | 29 | 89.66 (72.65–97.81) | 64.26 (35.14–87.24) | 2.20E−04 |
| Mikrogen | 43 | 29 | 79.31 (60.26–92.01) | 64.26 (35.14–87.24) | 4.94E−03 |
| IBL | 43 | 29 | 75.89 (56.46–89.7) | 64.26 (35.14–87.24) | 1.07E−02 |
a
The values for each test are reported as the determined Q fever phase II IgM level versus the IFAT result. 95% CI, 95% confidence interval.